Notably, Ocs-P administration conferred strong anticancer T cell immunity (multifunctional CD4+ and CD8+ immune responses) and significant protection to mice that received colon carcinoma cells, suggesting that Ocs-P will be potentially useful in developing nutraceuticals to improve anticancer immunity. This evidence concerns the gene CD8A and colon carcinoma.